Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled levodopa versus oral levodopa for OFF periods in Parkinson's disease
NL-OMON55857Phase 2Active, not recruiting
- Sponsor
- Martini Ziekenhuis
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of levodopa and benserazide in Parkinson's disease (PD) (2 arms), sponsored by Martini Ziekenhuis. Primary endpoint: Time until maximum effect on motor function. Started May 2019; status: active, not recruiting.
02
Drugs
levodopabenserazide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON55857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55857.